Skip to main content

STADA Value Stock - Dividend - Research Selection

STADA

ISIN: DE0007251803, WKN: 725180

Market price date: 29.05.2020
Market price: 90,50 EUR




STADA Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 15-03-2020
Cash flow
Net operating cash flow 444.080.000
Capital Expenditures -82.718.000
Free cash flow 361.361.984
Balance sheet
Total Equity 1.080.340.000
Liabilities & Shareholders equity 3.859.430.000
Income statement
Net income 302.697.000
Eps (diluted) 4,860
Diluted shares outstanding 62.283.300
Net sales/revenue 2.608.560.000

Fundamental ratios calculated on: 29-05-2020

Ratios
Key figures 29-05-2020
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI7,84
ROE27,99
Income statement
P/E18,62
Div. Yield0,00%
P/B0,00
P/S2,16


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolSAZ.HM
Market Capitalization6.276.880.384,00 USD
CountryGermany
IndicesCDAX,HDAX,Prime All Share
SectorsPharma
Raw Data SourceIFRS in Millionen EUR
Stock Split2004-08-02,2.0000/1.0000; 2000-10-02,10.0000/1.0000
Internetwww.stada.de


Description of the company

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson\'s medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.stada.de